Insider Selling: Inogen Inc. (INGN) EVP Sells 4,551 Shares of Stock
Inogen Inc. (NASDAQ:INGN) EVP Matt Scribner sold 4,551 shares of the business’s stock in a transaction that occurred on Monday, September 19th. The shares were sold at an average price of $60.18, for a total value of $273,879.18. Following the completion of the sale, the executive vice president now owns 6,884 shares of the company’s stock, valued at approximately $414,279.12. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Matt Scribner also recently made the following trade(s):
- On Thursday, August 18th, Matt Scribner sold 2,320 shares of Inogen stock. The shares were sold at an average price of $56.39, for a total value of $130,824.80.
- On Monday, July 18th, Matt Scribner sold 4,102 shares of Inogen stock. The shares were sold at an average price of $50.46, for a total value of $206,986.92.
Inogen Inc. (NASDAQ:INGN) opened at 60.20 on Thursday. The firm has a market capitalization of $1.21 billion, a P/E ratio of 88.53 and a beta of 0.88. The stock’s 50 day moving average price is $57.61 and its 200-day moving average price is $49.64. Inogen Inc. has a 12 month low of $28.81 and a 12 month high of $60.95.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/22/insider-selling-inogen-inc-ingn-evp-sells-4551-shares-of-stock.html
Inogen (NASDAQ:INGN) last announced its quarterly earnings results on Thursday, August 4th. The medical technology company reported $0.25 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.20 by $0.05. The business earned $54.57 million during the quarter, compared to the consensus estimate of $52.44 million. Inogen had a net margin of 7.86% and a return on equity of 9.50%. The business’s revenue was up 23.9% compared to the same quarter last year. During the same quarter last year, the firm earned $0.17 EPS. Equities analysts forecast that Inogen Inc. will post $0.63 earnings per share for the current year.
A number of analysts recently issued reports on the company. Zacks Investment Research lowered Inogen from a “buy” rating to a “hold” rating in a report on Tuesday, August 9th. JPMorgan Chase & Co. boosted their price objective on shares of Inogen from $60.00 to $62.00 and gave the stock an “overweight” rating in a research note on Friday, August 5th. Needham & Company LLC reissued a “strong-buy” rating and issued a $64.00 price objective (up previously from $58.00) on shares of Inogen in a research note on Sunday, August 7th. Stifel Nicolaus downgraded shares of Inogen from a “buy” rating to a “hold” rating in a research note on Friday, August 5th. They noted that the move was a valuation call. Finally, Leerink Swann reissued an “outperform” rating and issued a $60.00 price objective on shares of Inogen in a research note on Wednesday, June 8th. Three analysts have rated the stock with a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $55.00.
Several hedge funds have recently made changes to their positions in the company. Legal & General Group Plc increased its stake in shares of Inogen by 35.1% in the first quarter. Legal & General Group Plc now owns 2,738 shares of the medical technology company’s stock worth $117,000 after buying an additional 712 shares in the last quarter. Bayesian Capital Management LP purchased a new stake in shares of Inogen during the first quarter worth about $238,000. Renaissance Technologies LLC increased its stake in shares of Inogen by 4.7% in the first quarter. Renaissance Technologies LLC now owns 363,200 shares of the medical technology company’s stock worth $16,337,000 after buying an additional 16,300 shares in the last quarter. Bogle Investment Management L P DE purchased a new stake in shares of Inogen during the first quarter worth about $861,000. Finally, Geode Capital Management LLC increased its stake in shares of Inogen by 8.1% in the first quarter. Geode Capital Management LLC now owns 149,106 shares of the medical technology company’s stock worth $6,706,000 after buying an additional 11,169 shares in the last quarter.
Inogen Company Profile
Inogen, Inc is a medical technology company. The Company is engaged in developing, manufacturing and marketing portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The Company’s Inogen One systems concentrate the air around the patient to offer a single source of supplemental oxygen anytime, anywhere with a portable device weighing approximately 4.8 or seven pounds.
Receive News & Ratings for Inogen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.